Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates First Patient Dosed in Validive ® Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2021 ...
Source: forextv.com